LUPS-Lipids and Glucose Under Prospective Surveillance

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
City of Hamburg
Universitätsklinikum Hamburg-Eppendorf
Information provided by:
Asklepios proresearch
ClinicalTrials.gov Identifier:
NCT01313156
First received: March 10, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

Prospective, non-randomized cohort study to analyse genetic variations, dietary patterns, perceived stress and anxiety and early changes in lipid metabolism leading to the metabolic syndrome and type 2 diabetes


Condition
Metabolic Syndrome, Syndrome X, MetS,
Diabetes Mellitus, Non-Insulin-Dependent

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Lipids and Glucose Under Prospective Surveillance

Resource links provided by NLM:


Further study details as provided by Asklepios proresearch:

Primary Outcome Measures:
  • Metabolic Syndrome, Type 2 Diabetes [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    assessing risk factors, e.g. HDL, BMI, Blood Pressure, FPG


Enrollment: 1962
Study Start Date: November 2008
Estimated Primary Completion Date: May 2020 (Final data collection date for primary outcome measure)
Detailed Description:

The LUPS-study is a collaboration between Asklepios Clinics Hamburg GmbH and University Clinic Hamburg Eppendorf, Germany. This study is assessing a multitude of serum biomarkers, anthropometrics, dietary habits, physical activity, perceived stress along with genetic information from "healthy workers" (25-60years) to better understand phenotype-genotype associations leading to MetS and type 2 diabetes.

  Eligibility

Ages Eligible for Study:   25 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

so-called "Healthy-Workers", aged 25-60years, of Lufthansa-Technik, Hamburg, Germany, who voluntarily aggreed to participate in the study.

Criteria

Inclusion Criteria:

  • 25-60 years men and women willing to give consent

Exclusion Criteria:

  • diabetes (type 1 or 2)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01313156

Locations
Germany
Asklepios Klinik St.Georg
Hamburg, Germany, 20099
Universitätsklinikum Eppendorf
Hamburg, Germany, 20246
Sponsors and Collaborators
Asklepios proresearch
City of Hamburg
Universitätsklinikum Hamburg-Eppendorf
Investigators
Principal Investigator: Dirk Mueller-Wieland, Prof., MD Asklepios Klinik St.Georg, Hamburg, Germany
Principal Investigator: Karl Wegscheider, Prof., PHD Universitätsklinikum Hamburg Eppendorf, Germany
  More Information

No publications provided

Responsible Party: 1.Prof. Mueller-Wieland; 2.Prof.Wegscheider, 1.Asklepios Klinik St.Georg, I.Med.; 2. Universitätsklinikum HH-Eppendorf, Abtlg.f. Epidemiologie
ClinicalTrials.gov Identifier: NCT01313156     History of Changes
Other Study ID Numbers: AKS#1833
Study First Received: March 10, 2011
Last Updated: March 10, 2011
Health Authority: Germany: Ethics Commission

Keywords provided by Asklepios proresearch:
Metabolic Syndrome, Syndrome X, MetS,
Type 2 Diabetes

Additional relevant MeSH terms:
Metabolic Syndrome X
Diabetes Mellitus
Diabetes Mellitus, Type 2
Syndrome
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Hyperinsulinism
Endocrine System Diseases
Disease
Pathologic Processes

ClinicalTrials.gov processed this record on September 16, 2014